Research guide / Kisspeptin

What is Kisspeptin? A Complete Research Guide.

Updated August 2026 · 9 minute read

Kisspeptin is an endogenous peptide that acts as a master switch of the reproductive hormone axis, studied in human IVF and neuroendocrine research. This guide separates the published human studies from what regulators have actually said.

Research information only. This article summarises published research. It is not medical advice, a dosing guide, or a recommendation to use any product. Early-phase human findings do not predict an individual outcome, and kisspeptin is not an approved medicine.

01 / Overview

What is kisspeptin?

Kisspeptin is a family of peptides encoded by the human KISS1 gene, named after the chocolate 'Kisses' of Hershey, Pennsylvania, where the gene was first studied. It acts through the KISS1 receptor (formerly GPR54) and sits at the top of the reproductive hormone cascade: kisspeptin neurons in the hypothalamus control the release of GnRH, which in turn drives LH and FSH — the hormones that govern puberty, ovulation, and fertility.[1]

Loss-of-function mutations in kisspeptin signalling cause failure of puberty and infertility, which established it as a master regulator of the reproductive axis. That biology made it a research tool: the major circulating form, kisspeptin-54, can be administered to stimulate the body's own reproductive hormone release in a controlled, physiological way.[2]

The critical context: kisspeptin has unusually real human data for a research peptide — small, controlled studies run mainly by one academic group at Imperial College London. But these are early-phase, single-centre studies of dozens of participants, not the large multi-centre trials behind an approved medicine. No kisspeptin product is approved anywhere.

View the kisspeptin research listing

02 / Mechanism

How does kisspeptin work?

Kisspeptin binds the KISS1 receptor on GnRH neurons in the hypothalamus, stimulating the pulsatile release of GnRH. GnRH then acts on the pituitary to release LH and FSH, which act on the ovaries or testes. Because it works upstream, administered kisspeptin raises the body's own reproductive hormones rather than supplying a hormone directly.[1], [2]

Aspect	What research reports	Research relevance
KISS1 receptor activation	Kisspeptin binds KISS1R on hypothalamic GnRH neurons, triggering GnRH release.	The upstream switch of the reproductive axis.
LH / FSH stimulation	GnRH drives pituitary release of LH and FSH; kisspeptin-54 raises these hormones in humans.	The basis for its use as a physiological stimulus in studies.
Brief, physiological action	Kisspeptin stimulates the body's own short LH surge rather than supplying a long-acting hormone.	The hypothesis behind its study as a potentially gentler IVF trigger.

This pathway is well characterised in human physiology studies. What has not been established is any approved therapeutic use: the human studies test whether kisspeptin can trigger a physiological response, not whether it treats a condition better than existing medicines.

03 / Published evidence

Peer-reviewed findings

Jayasena, Abbara et al. 2014 (Journal of Clinical Investigation) ran the first-in-human test of kisspeptin-54 as an IVF 'trigger': 53 women undergoing IVF received a single injection to induce egg maturation instead of the standard hCG trigger. Egg maturation was achieved, and live births followed — a proof of concept, not a comparison against standard care.[2]

Abbara et al. 2015 (JCEM) followed with a Phase 2 randomised trial in 60 women at high risk of ovarian hyperstimulation syndrome (OHSS), a dangerous complication of IVF. Kisspeptin-54 triggered egg maturation across dose groups. The rationale: because kisspeptin stimulates the body's own LH surge briefly, it may carry a lower OHSS risk than hCG — a hypothesis these early studies were designed to explore, not to prove.[3]

Comninos et al. 2017 (Journal of Clinical Investigation) took the research in a different direction: in a randomised, placebo-controlled neuroimaging study of 29 healthy young men, kisspeptin administration enhanced limbic brain activity in response to sexual and couple-bonding stimuli and attenuated negative mood. This links the reproductive axis to brain processing — an early mechanistic finding, not evidence of a treatment effect.[1]

Read precisely, the human evidence shows kisspeptin does what its biology predicts: it stimulates the reproductive axis in people. What the evidence does not show is superiority over existing medicines, long-term safety, or any outcome in the contexts it is marketed for online. The entire human literature consists of small, early-phase studies from a small number of research groups.

04 / Evidence landscape

How the evidence is structured

Kisspeptin has genuine human studies but no large registered clinical trial programme and no regulatory submission. The table below maps the published evidence base.

Category	Example	Scale	What it can show
Human physiology studies	Imperial College London programme	Dozens of volunteers	Kisspeptin stimulates reproductive hormone release in people
IVF trigger proof of concept	Jayasena/Abbara et al., 2014	53 women	A single kisspeptin-54 dose can trigger egg maturation
Phase 2 randomised trial	Abbara et al., 2015	60 women at high OHSS risk	Egg maturation across dose groups; safety hypothesis explored
Neuroimaging RCT	Comninos et al., 2017	29 men	Limbic brain responses to sexual and bonding stimuli
Large confirmatory trials	None exist	—	No evidence of superiority, long-term safety, or approved use

This mapping reflects the published records reviewed for this August 2026 update. The pattern to notice: real human data exists, but every row is small, early-phase, and academic — none is the kind of trial that supports an approved medicine.[1], [2], [3]

Afiya Labs lists a kisspeptin reference material for laboratory research. The catalogue entry is not a medicine listing and is not presented as suitable for human use.

See the kisspeptin catalogue entry

Shop Kisspeptin pen

05 / Safety evidence

What safety evidence exists?

In the published IVF studies, single doses of kisspeptin-54 were generally well tolerated in the studied women, and the OHSS-risk trial was specifically designed around a safety hypothesis. But these studies were small, short, and conducted under clinical supervision — they cannot establish a general safety profile.[2], [3]

The U.S. FDA has placed kisspeptin-10 in Category 2 of its interim compounding policy — bulk substances identified as potentially presenting significant safety risks in compounding. Category placement is a regulatory risk signal, not a full safety assessment, and it concerns compounded products.[4]

There is no published safety data for repeated self-administration, for use outside a clinical protocol, or in men outside the small neuroimaging studies. Anyone reading claims about kisspeptin use should weigh them against how thin the controlled human data is.

06 / Regulators

Status in the US, Europe, and UAE

United States

Kisspeptin is not an FDA-approved drug. Under the FDA's interim compounding policy, kisspeptin-10 appears in Category 2 — bulk substances that may present significant safety risks in compounding. This category concerns pharmacy compounding and is not a marketing authorisation.[4]

European Union

Kisspeptin is not authorised as a medicine in the EU. The human studies cited here were academic research conducted under clinical trial approvals, not steps toward a marketing authorisation.

United Arab Emirates

The Emirates Drug Establishment maintains the UAE's public registered medical product directory. We did not rely on a directory search to infer approval, non-approval, legality, availability, or permission for use of any specific product; those questions require confirmation from the EDE. Approved medicines in the UAE are dispensed through licensed channels.[5]

07 / Quick answers

Frequently asked questions

Is kisspeptin an approved medicine?

No. Kisspeptin is not approved as a drug in the US, authorised as a medicine in the EU, or approved anywhere else. The human studies were academic research, not a regulatory development programme.

Is kisspeptin natural?

Yes — kisspeptin is encoded by the human KISS1 gene and produced by the body as a master regulator of the reproductive axis. Research materials are synthetically produced copies of the natural sequence.

Does kisspeptin have real human studies?

Yes — unusually for a research peptide. Small controlled studies show kisspeptin-54 can trigger egg maturation in IVF and that kisspeptin modulates limbic brain activity in men. But all are early-phase, single-centre studies of dozens of participants.

Is kisspeptin proven for libido or fertility treatment?

No. The brain-imaging study measured brain activity, not libido outcomes, and the IVF studies were proofs of concept in supervised clinical settings. No study shows kisspeptin treats any condition better than existing medicines.

How is kisspeptin different from PT-141?

PT-141 (bremelanotide) acts on melanocortin receptors in the brain and is an FDA-approved drug for a specific indication. Kisspeptin acts upstream on the reproductive hormone axis and has no approval anywhere.

What does the UAE directory show?

It is a public register of medical products. This guide does not turn a directory search result — or the absence of one — into a claim about approval, legality, or permitted use. The EDE is the appropriate authority for a current determination.

08 / Sources